Vantive is a vital organ therapy company established in 2025, building upon a 70-year legacy of kidney care innovation. The company operates in more than 100 countries, serving a global patient population with over one million daily touchpoints.
Its work centers on dialysis therapies, which include products and services for both home and clinical settings, and critical care therapies for kidney and other vital organ support in intensive care units. A key technical focus is remote patient monitoring technology for home dialysis patients; this technology is associated with improved patient outcomes, including lower mortality rates, fewer hospitalizations, and greater treatment adherence.
